Food for thought:
Sarepta was a US $60 million Coy.
After their phase 2 they went to $6 billion MC
Anp is similar .. hardly any interest..
however when you look at the RISK REWARD Itsa scratches his head..$$
Sarepta entering into P2 was a one trick pony
Anp not only going into P2+ have proved
the end points in P2 going into P2+
Have multiple other indications to fall back on eg
Fibrosis. Neuromuscular and Neurodegenerative
diseases etc.
Sarepta did not have the backing of the FDA and still don’t…
Anp on the other hand has the backing of the FDA and was asked to file for FastTrack. Designation.
Ann: Positive feedback received on Paediatric Investigation Plan, page-55
-
- There are more pages in this discussion • 167 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $21.40K | 203.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 215964 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 341886 | 4 |
View Market Depth
| Last trade - 10.06am 07/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |